22,901 Johnson & Johnson $JNJ Shares Acquired by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 48.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 70,070 shares of the company’s stock after acquiring an additional 22,901 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Johnson & Johnson were worth $18,551,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BHK Investment Advisors LLC acquired a new stake in Johnson & Johnson during the third quarter worth $203,000. Bluebird Wealth Management LLC grew its holdings in Johnson & Johnson by 3.7% during the 3rd quarter. Bluebird Wealth Management LLC now owns 4,222 shares of the company’s stock worth $1,166,000 after acquiring an additional 150 shares during the last quarter. Independent Advisor Alliance raised its position in Johnson & Johnson by 5.9% in the 3rd quarter. Independent Advisor Alliance now owns 106,213 shares of the company’s stock worth $28,454,000 after purchasing an additional 5,953 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in Johnson & Johnson by 26.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 148,668 shares of the company’s stock worth $39,358,000 after purchasing an additional 31,476 shares during the last quarter. Finally, MA Private Wealth boosted its stake in Johnson & Johnson by 15.7% in the third quarter. MA Private Wealth now owns 1,633 shares of the company’s stock valued at $432,000 after acquiring an additional 222 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Tuesday, September 29th. Royal Bank Of Canada decreased their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. Evercore set a $300.00 price target on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Finally, UBS Group set a $270.00 target price on Johnson & Johnson in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Get Our Latest Analysis on Johnson & Johnson

Insiders Place Their Bets

In other news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

These are some of the JNJ stories that stood out recently:

  • Positive Sentiment: J&J plans to acquire Ollin Biosciences, adding a Phase III retinal-disease candidate to its ophthalmology pipeline. Reports cite a $2.2 billion deal, potentially worth up to $3.3 billion; Blackstone is expected to contribute $750 million toward development. UBS sees the asset as a possible growth driver beyond 2030. Article: Planned Ollin acquisition as a growth driver
  • Neutral Sentiment: The reported average analyst price target is $275.92, near the share price cited in the provided market data; the target offers little clear near-term direction on its own. Article: JNJ average price target
  • Negative Sentiment: Shares came under pressure following insider selling, which can raise concerns about executives’ view of near-term prospects, though it does not by itself establish a change in the company’s outlook. Article: JNJ share weakness following insider selling

Johnson & Johnson Stock Down 2.1%

Shares of NYSE JNJ opened at $272.75 on Thursday. The company has a 50 day simple moving average of $267.42 and a 200 day simple moving average of $250.61. Johnson & Johnson has a 1 year low of $199.38 and a 1 year high of $290.25. The firm has a market cap of $656.58 billion, a PE ratio of 26.17, a price-to-earnings-growth ratio of 2.75 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.